AU2002340139A1 - Inhibitors of the egf receptor for the treatment of thyroid cancer - Google Patents

Inhibitors of the egf receptor for the treatment of thyroid cancer

Info

Publication number
AU2002340139A1
AU2002340139A1 AU2002340139A AU2002340139A AU2002340139A1 AU 2002340139 A1 AU2002340139 A1 AU 2002340139A1 AU 2002340139 A AU2002340139 A AU 2002340139A AU 2002340139 A AU2002340139 A AU 2002340139A AU 2002340139 A1 AU2002340139 A1 AU 2002340139A1
Authority
AU
Australia
Prior art keywords
inhibitors
treatment
thyroid cancer
egf receptor
egf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002340139A
Other languages
English (en)
Inventor
James Alexander Fagin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Cincinnati
Original Assignee
University of Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Cincinnati filed Critical University of Cincinnati
Publication of AU2002340139A1 publication Critical patent/AU2002340139A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002340139A 2001-10-09 2002-10-08 Inhibitors of the egf receptor for the treatment of thyroid cancer Abandoned AU2002340139A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32788001P 2001-10-09 2001-10-09
US60/327,880 2001-10-09
PCT/US2002/032195 WO2003030908A2 (en) 2001-10-09 2002-10-08 Inhibitors of the egf receptor for the treatment of thyroid cancer

Publications (1)

Publication Number Publication Date
AU2002340139A1 true AU2002340139A1 (en) 2003-04-22

Family

ID=23278480

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002340139A Abandoned AU2002340139A1 (en) 2001-10-09 2002-10-08 Inhibitors of the egf receptor for the treatment of thyroid cancer

Country Status (5)

Country Link
US (1) US20040191254A1 (enExample)
EP (1) EP1435959A2 (enExample)
JP (1) JP2005531488A (enExample)
AU (1) AU2002340139A1 (enExample)
WO (1) WO2003030908A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230302B1 (hu) * 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
US7994159B2 (en) * 2003-03-10 2011-08-09 Eisai R&D Management Co., Ltd. c-Kit kinase inhibitor
EP1493445A1 (en) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
WO2005039588A2 (en) * 2003-10-22 2005-05-06 Novartis Ag Methods for determining the risk of developing liver and lung toxicity
CN101337930B (zh) * 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
TW200529849A (en) * 2003-11-28 2005-09-16 Novartis Ag Diaryl urea derivatives in the treatment of protein kinase dependent diseases
EP1797881B1 (en) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Medicinal composition with improved stability and reduced gelation properties
EP1925941B1 (en) * 2005-08-01 2012-11-28 Eisai R&D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
AU2006309551B2 (en) * 2005-11-07 2012-04-19 Eisai R & D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
EP1964837A4 (en) * 2005-11-22 2010-12-22 Eisai R&D Man Co Ltd Antitumor agent against multiple myeloma
ES2556173T3 (es) * 2006-05-18 2016-01-13 Eisai R&D Management Co., Ltd. Agente antitumoral para un cáncer de tiroides
EP2044939A1 (en) * 2006-06-29 2009-04-08 Eisai R&D Management Co., Ltd. Therapeutic agent for liver fibrosis
CN101511793B (zh) * 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
KR101445892B1 (ko) * 2007-01-29 2014-09-29 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암 치료용 조성물
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
JP5399926B2 (ja) * 2008-01-29 2014-01-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管阻害物質とタキサンとの併用
PE20120105A1 (es) 2009-03-11 2012-02-22 Ardea Biosciences Inc Combinaciones farmaceuticas que comprenden refametinib
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
RU2580609C2 (ru) 2011-04-18 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
JP5759568B2 (ja) 2012-09-25 2015-08-05 中外製薬株式会社 Ｒｅｔ阻害剤
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
WO2014185540A1 (en) 2013-05-14 2014-11-20 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
KR102329681B1 (ko) 2014-08-28 2021-11-23 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
KR20250024102A (ko) 2015-02-25 2025-02-18 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 고미 억제 방법
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
SG11201801083UA (en) 2015-08-20 2018-03-28 Eisai R&D Man Co Ltd Tumor therapeutic agent
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
US20200197384A1 (en) 2017-05-16 2020-06-25 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747598A (en) * 1990-01-16 1998-05-05 Mobil Oil Corporation Epoxidized solid elastomeric copolymers
KR100240308B1 (ko) * 1991-03-06 2000-01-15 플레믹 크리스티안 인간화된단클론성항체및혼성단클론성항체
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
ATE212993T1 (de) * 1995-07-06 2002-02-15 Novartis Erfind Verwalt Gmbh Pyrolopyrimidine und verfahren zu ihrer herstellung
WO1997049798A1 (en) * 1996-06-27 1997-12-31 University Of Helsinki Glial cell line-derived neurotrophic factor regulation of ureteric budding and growth, and of enteric innervation
WO1998045708A1 (en) * 1997-04-08 1998-10-15 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
US6987113B2 (en) * 1997-06-11 2006-01-17 Sugen, Inc. Tyrosine kinase inhibitors
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
GB0031080D0 (en) * 2000-12-20 2001-01-31 Novartis Ag Organic compounds
GB0119249D0 (en) * 2001-08-07 2001-10-03 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US20040191254A1 (en) 2004-09-30
EP1435959A2 (en) 2004-07-14
WO2003030908A3 (en) 2003-11-06
JP2005531488A (ja) 2005-10-20
WO2003030908A2 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
AU2002340139A1 (en) Inhibitors of the egf receptor for the treatment of thyroid cancer
PL375532A1 (en) Benzimidazol-1-yl-thiophene compounds for the treatment of cancer
AU2002360766A1 (en) Methods for cancer imaging
EP1372736A4 (en) PREPARATIONS AGAINST CANCER FORMATION
AU2003224076A1 (en) Antibody combination useful for tumor therapy
AU2002252456A1 (en) Combination treatment of pancreatic cancer
AU2002328952A1 (en) Irinotecan for treatment of cancer
AUPR395801A0 (en) Antibodies against cancer
AU2000258650A1 (en) 2-piperidone compounds for the treatment of cancer
AU2002305333A1 (en) Compounds and methods for the modulation of cd154
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
AU2001290165A1 (en) Components of canola for the treatment of cancer
AU2002320098A1 (en) Dye-azide compounds for dual phototherapy
AU8322401A (en) Indole compounds useful for the treatment of cancer
AU2002353739A1 (en) Therapeutic compounds
AU2002308642A1 (en) Methods for treating cancer
HUP0402341A3 (en) Compositions containing thiazol-2-ylamines for the treatment of cancer
AU2003223538A1 (en) Methods for the treatment of cancer
AU2002304883A1 (en) Device for the treatment of tumours
AU2003296242A1 (en) Thia-epothilone derivatives for the treatment of cancer
AU2002359916A1 (en) Preventives/remedies for cancer
AU2000263936A1 (en) Substance p analogs for the treatment of cancer
AU2002351382A1 (en) Combination cancer therapy
AU2002366272A1 (en) Edg-receptor agonist for the treatment of hypertension
HK1080458A (en) Benzimidazol-1-yl-thiophene compounds for the treatment of cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase